Baxter shares dented by HemAssist data demand
This article was originally published in Clinica
Despite the strong dollar, Baxter's sales rose 14% in both the third quarter and the first nine months, to $1,494 million and $4,506 million. However, last week its share price was hit by news that the European drug regulatory agency has asked for further clinical data on its blood substitute, HemAssist.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.